Scientific recognition
Muhammad Usman Mirza, CSO at Pharmaeconomica, recognized among SciRank Global’s Top 5% Scientists
In May 2026, Muhammad Usman Mirza, Chief Scientific Officer at Pharmaeconomica, was listed among SciRank Global’s Top 5% Scientists through the Global Scientist Index.
This recognition highlights the scientific strength behind Pharmaeconomica’s drug discovery activities and supports the company’s ambition to develop PreditX® as a credible, science-driven AI platform for early drug discovery.
Trademark
PreditX® registered as a European Union trademark
In May 2026, PreditX® was registered as a European Union trademark.
This strengthens the commercial identity of the platform and supports Pharmaeconomica’s strategy to position PreditX® as a distinct AI-driven drug discovery product.
The trademark registration represents an important step in protecting the PreditX® brand as the platform continues to evolve toward predictive screening, ADMET & Developability Profiling, and Generative AI-supported molecular design.
Platform milestone
PreditX® completes VLAIO feasibility project with positive results
In April 2026, Pharmaeconomica completed the VLAIO feasibility project with positive results.
The project confirmed that a Generative AI module can be integrated into PreditX® as a valuable extension of the platform’s predictive engine. The feasibility work showed that generated molecule ideas can be connected to downstream ranking, filtering, and review logic inside the PreditX® workflow.
As part of the project, Pharmaeconomica also completed a benchmark analysis using ChEMBL-derived targets to test the robustness and generalizability of the PreditX® approach. The benchmark supported the platform’s ability to operate beyond isolated examples and provided evidence for continued development of the Generative AI module.
Product update
PreditX® integrates ADMET & Developability Profiling module
As part of the platform expansion, PreditX® integrated an ADMET & Developability Profiling module.
ADMET stands for absorption, distribution, metabolism, excretion, and toxicity. In practical terms, the module helps users look beyond predicted activity and assess whether candidate molecules appear more suitable for follow-up.
The ADMET module is designed as a decision-support layer. It helps users review candidate molecules more systematically, identify potential developability concerns earlier, and prioritize compounds for further analysis.
Innovation grant
Pharmaeconomica awarded VLAIO feasibility grant to explore Generative AI integration in PreditX®
In September 2025, Pharmaeconomica was awarded a feasibility grant by VLAIO to assess the integration of a Generative AI module into PreditX®.
The project focused on evaluating whether PreditX® could move beyond predictive virtual screening and support the generation of new, chemically meaningful molecule ideas within the same no-code discovery workflow.
This grant marked an important step in the evolution of PreditX® from a predictive screening platform toward a broader AI-supported discovery environment.